BioDuro has announced the launch of a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners.
The new BU underscores the company’s commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.
The peptide BU, which is already fully operational, will be led by Dr Fengping Xiao, who brings decades of experience to his newly created role spanning from drug discovery through development.
During the past couple of years, BioDuro has built comprehensive peptide capabilities across multiple technology platforms, including its newly established DNA-encoded library (DEL) screening service and AI-enabled design for peptides.
The new BU will integrate BioDuro’s chemistry, biology, DMPK, drug substance and drug product capabilities into a single specialised platform.
It will combine the company’s cross-functional peptide expertise, dedicated resources and customised workflows to accelerate peptide drug discovery and development under one roof.
“Our goal is to provide comprehensive scientific expertise and fully integrated solutions by bringing together the best minds and technologies to deliver optimal results for our global partners,” said Dr Xiao.
“The creation of this Peptide BU marks a pivotal milestone for BioDuro,” added Dr Armin Spura, CEO of BioDuro.
“Our mission is to build the most advanced peptide platform, powered by exceptional science, state-of-the-art technology and a world-class team, to meet the growing customer demand for complex peptide therapeutics worldwide.”